Astria Therapeutics, Inc. logo ATXS - Astria Therapeutics, Inc.

Inactive Ticker ATXS is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 3
HOLD 5
SELL 0
STRONG
SELL
0
| PRICE TARGET: $19.40 DETAILS
HIGH: $26.00
LOW: $13.00
MEDIAN: $20.00
CONSENSUS: $19.40
UPSIDE: 54.21%

Stock News

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Stockholders Vote to Approve Acquisition by BioCryst

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. About Astria Therapeutics Astria Therapeutics is a biopharmaceutical company, whose mission i.

Jan 21, 2026 11:00 AM businesswire.com
Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)

Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) and Astria Therapeutics (NASDAQ: ATXS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Valuation and Earnings This table compares Swedish

Jan 17, 2026 10:10 PM defenseworld.net

Price Targets